高危透明细胞肾细胞癌中辅助帕博利珠单抗的风险依赖性获益:多中心研究
该回顾性多中心队列纳入739例符合KEYNOTE-564标准且接受手术的透明细胞肾细胞癌患者,其中288例接受辅助帕博利珠单抗、451例监测,中位随访18.4个月。90天内启动帕博利珠单抗与无病生存无显著关联,但绝对获益在高基线复发风险组更大,交互作用不显著。
要点
- 符合KEYNOTE-564标准者基线复发风险差异显著,需个体化评估。
- 90天内启动帕博利珠单抗与DFS无显著关联(多因素HR 0.91)。
- 16%接受帕博利珠单抗者发生≥3级免疫相关不良事件。
核心结论
- 符合KEYNOTE-564标准的患者基线复发风险差异明显,潜在绝对获益随基线风险升高而增大,但交互作用不显著。
研究设计与样本
- 回顾性队列纳入五个美国三级中心2021-2025年连续收治的739例符合KEYNOTE-564标准且接受手术的ccRCC患者,288例接受辅助帕博利珠单抗、451例监测。
主要发现
- 接受治疗者不良病理特征更多,16%发生≥3级免疫相关不良事件。
- 标志性队列686例中212例在90天内启动帕博利珠单抗,中位随访19.8个月。
- 90天内启动帕博利珠单抗与DFS无显著关联:未调整HR 1.02,多因素调整HR 0.91,IPTW分析HR 0.90。
- 标志点后18个月, favoring帕博利珠单抗的绝对风险差在低、中、高危组分别为-9.4%、3.6%、5.7%(交互作用P=0.8)。
关键数值与推荐
- 90天内启动帕博利珠单抗与DFS无显著关联(未调整HR 1.02;多因素HR 0.91;IPTW HR 0.90)。
- 标志点后18个月绝对风险差:低危-9.4%、中危3.6%、高危5.7%(交互作用P=0.8)。
临床怎么用
- 术后辅助治疗决策应结合个体复发风险与潜在毒性进行个体化咨询。
- 高危患者可能从辅助帕博利珠单抗获得更大绝对获益,但需注意16%的≥3级免疫相关不良事件。
局限性
- 非随机治疗分配。
- 随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adjuvant pembrolizumab improves outcomes in high-risk clear cell renal cell carcinoma (ccRCC), but baseline recurrence risk varies substantially. OBJECTIVE: To evaluate treatment selection, outcomes, toxicity, and risk-stratified benefit. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort of consecutive patients with KEYNOTE-564-eligible ccRCC treated surgically at five U.S. tertiary centers (2021-2025). INTERVENTION: Adjuvant pembrolizumab or surveillance, selected through routine care. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Disease-free survival (DFS) was evaluated using a 90-day postoperative landmark, multivariable Cox regression, and inverse probability of treatment weighting (IPTW), stratified by ASSURE risk category. Immune-related adverse events were assessed. RESULTS AND LIMITATIONS: Among 739 patients, 288 received pembrolizumab and 451 underwent surveillance; median follow-up was 18.4 months. Treated patients had more adverse pathologic features; 16% experienced grade ≥3 immune-related adverse events. The landmark cohort included 686 patients with median follow-up of 19.8 months, including 212 who initiated pembrolizumab by 90 days. Initiation by 90 days was not significantly associated with DFS in unadjusted (hazard ratio 1.02), multivariable-adjusted (0.91), or IPTW analyses (0.90). At 18 months after the landmark, absolute risk differences favoring pembrolizumab were -9.4%, 3.6%, and 5.7% across low-, intermediate-, and high-risk groups, respectively (interaction p = 0.8). Limitations include nonrandomized treatment allocation and limited follow-up. CONCLUSIONS: Baseline recurrence risk varied markedly among eligible patients. Potential absolute benefit appeared greater with higher baseline risk, although the interaction was nonsignificant. Individualized counseling and improved prognostic and predictive tools remain important. PATIENT SUMMARY: After kidney cancer surgery, treatment decisions should consider individual recurrence risk and potential side effects. Serious toxicity affected 16% of recipients.
引用
- Shapiro DD, Roadman DF, Master VA, et al. Risk-dependent Benefit of Adjuvant Pembrolizumab in High-risk Clear Cell Renal Cell Carcinoma: A Multi-institutional Study. Eur Urol Oncol. 2026. PMID: 42744717. doi:10.1016/j.euo.2026.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。